LENZ Therapeutics, Inc.
LENZ
$4.73
$0.132.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.72% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.72% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.12% | -- | -- | -- | -- |
| SG&A Expenses | 207.74% | 304.57% | 323.57% | 324.95% | 72.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.44% | 171.90% | 163.06% | 142.46% | 52.29% |
| Operating Income | -102.72% | -160.68% | -152.63% | -45.90% | -17.45% |
| Income Before Tax | -121.45% | -183.80% | -183.72% | -63.49% | -40.55% |
| Income Tax Expenses | -99.40% | -- | 100.00% | -- | -- |
| Earnings from Continuing Operations | -114.04% | -183.80% | -183.72% | -63.49% | -45.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.04% | -183.80% | -183.72% | -63.49% | -45.43% |
| EBIT | -102.72% | -160.68% | -152.63% | -45.90% | -17.45% |
| EBITDA | -102.29% | -160.57% | -152.34% | -45.05% | -17.47% |
| EPS Basic | -91.55% | -149.16% | -151.04% | -55.65% | -32.64% |
| Normalized Basic EPS | -95.45% | -149.17% | -151.04% | -55.62% | -15.35% |
| EPS Diluted | -91.55% | -149.16% | -151.04% | -55.65% | -32.64% |
| Normalized Diluted EPS | -95.45% | -149.17% | -151.04% | -55.62% | -15.35% |
| Average Basic Shares Outstanding | 11.74% | 13.90% | 13.02% | 5.04% | 9.65% |
| Average Diluted Shares Outstanding | 11.74% | 13.90% | 13.02% | 5.04% | 9.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |